4.4 Review

Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings

期刊

MALARIA JOURNAL
卷 21, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12936-022-04173-y

关键词

Malaria; Vectors; Transmission-blocking vaccines

资金

  1. European & Developing Countries Clinical Trials Partnership (EDCTP) through the Multi-Stage Malaria Control Consortium [RIA2016V-1649]
  2. Wellcome Trust
  3. EDCTP grant

向作者/读者索取更多资源

This article discusses the immunological mechanisms underlying malaria transmission blocking, the status of Pfs25-based vaccines, and the approaches and capacity for first in-human evaluation in endemic settings. It is concluded that supporting low and middle income countries to conduct first-in human vaccine trials is crucial.
Malaria control relies heavily on the use of anti-malarial drugs and insecticides against malaria parasites and mosquito vectors. Drug and insecticide resistance threatens the effectiveness of conventional malarial interventions; alternative control approaches are, therefore, needed. The development of malaria transmission-blocking vaccines that target the sexual stages in humans or mosquito vectors is among new approaches being pursued. Here, the immunological mechanisms underlying malaria transmission blocking, status of Pfs25-based vaccines are viewed, as well as approaches and capacity for first in-human evaluation of a transmission-blocking candidate vaccine Pfs25-IMX313/Matrix-M administered to semi-immune healthy individuals in endemic settings. It is concluded that institutions in low and middle income settings should be supported to conduct first-in human vaccine trials in order to stimulate innovative research and reduce the overdependence on developed countries for research and local interventions against many diseases of public health importance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据